Geneos Wealth Management Inc. Has $8.22 Million Stake in Eli Lilly and Company (NYSE:LLY)

Geneos Wealth Management Inc. trimmed its position in Eli Lilly and Company (NYSE:LLY) by 7.3% during the second quarter, HoldingsChannel.com reports. The fund owned 9,078 shares of the company’s stock after selling 716 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $8,219,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Tidemark LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. increased its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new position in Eli Lilly and Company in the second quarter valued at approximately $32,000. Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $37,000. Finally, St. Johns Investment Management Company LLC grew its stake in shares of Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after buying an additional 37 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold 1,122,141 shares of company stock worth $991,938,411 in the last quarter. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Up 0.5 %

LLY stock traded up $4.65 during mid-day trading on Friday, reaching $958.82. The company’s stock had a trading volume of 247,840 shares, compared to its average volume of 3,085,240. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The business’s 50 day moving average price is $884.83 and its 200 day moving average price is $812.10. The company has a market cap of $911.27 billion, a price-to-earnings ratio of 141.38, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on LLY shares. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Bank of America raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Guggenheim boosted their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price target for the stock from $725.00 to $1,025.00 in a report on Monday, August 12th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $956.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.